Feedback / Questions
VS-7375 - Verastem
https://www.businesswire.com/news/home/20250624162735/en/Verastem-Oncology-Announces-First-Patient-Dosed-with-VS-7375-an-Oral-KRAS-G12D-ONOFF-Inhibitor-in-a-U.S.-Phase-12a-Trial-in-KRAS-G12D-Advanced-Solid-Tumors
Jun 24, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next